Many patients diagnosed with multiple sclerosis experience a form of the disease known as relapsing-remitting MS
. They experience flare-ups when the immune system attacks the central nervous system. Recovery periods may follow the flare-ups as the disease moves into remission. Disease modifying drugs are prescribed to help reduce inflammation and disease activity. A new study examines the long-term use of beta interferon for patients with relapsing-remitting MS. Catherine Dolf explains in this week’s JAMA Report.